The receptor for epidermal growth factor (EGF) is a transmembrane glycoprotein with intrinsic tyrosine kinase activity (Ullrich and Schlessinger, 1990) . Many human cancers of epithelial origin express high numbers of EGF receptors and are stimulated by activation of the receptor via a transforming growth factor-α (TGF-α)/EGF receptor autocrine loop (Ozanne et al, 1986; Cowley et al, 1986; Ishitoya et al, 1989; Hendler and Ozanne, 1984) . The increased receptor levels are associated with poor clinical prognosis in patients with cancers of the bladder (Neal et al, 1985) , breast , and lung (Veale et al, 1987) and others. Blockade of EGF receptor as an approach for anticancer therapy has been extensively studied over the past decade (Fan and Mendelsohn, 1998) .
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Monoclonal antibody (mAb) 225 binds to EGF receptor with an affinity similar to that of the natural ligands EGF and TGF-α, competes with these natural ligands for receptor binding, and inhibits ligand-induced activation of the receptor tyrosine kinase (Sato et al, 1983; Gill et al, 1984) . This antibody, along with other EGF receptor-blocking mAbs, inhibits the proliferation of a variety of cultured and xenografted tumour cell lines that are stimulated by the TGF-α/EGF receptor autocrine loop, including cell lines derived from cancers of the vulva (Fan et al, 1993a; 1994) , breast (Ennis et al, 1989) , prostate (Peng et al, 1996; Hofer et al, 1991) , ovary (Ye et al, 1999) , bladder (Perrotte et al, 1999) , kidney (Prewett et al, 1998) , lung (Lee et al, 1992) , colon (Karnes et al, 1992; Wu et al, 1996) , brain (Wersall et al, 1997) , and head and neck (Modjtahedi et al, 1993) . It has been postulated that these antibodies inhibit tumour cell proliferation by an antibody-mediated interruption of the autocrine activation of EGF receptors in cancer cells (Van de Vijver et al, 1991; Fan et al, 1993b; Baselga et al, 1996) . The antibody-mediated growth inhibition in most malignant cell lines has been attributed primarily to a reduced proliferation rate with an increased cell population in G1 phase of the cell cycle (Fan et al, 1997; Wu et al, 1996; Peng et al, 1996) . In nonmalignant epithelial cells there was a prominent cytostatic effect with complete G1 arrest (Stampfer et al, 1993; Chou et al, 1999) .
DiFi colon cancer cells are unique in that exposure of these cells to mAb 225 resulted in not only G1 phase arrest of cell cycle, with a concomitant increase in the level of p27 Kip1 and a decrease in CDK activity, but also subsequent cell death through apoptosis (Wu et al, 1995; . When nude mice bearing well-established subcutaneous DiFi cell xenografts were treated with mAb 225, the tumour was completely eradicated, a result not normally seen with other cancer cells stimulated by the TGF-α/EGF receptor autocrine pathway (Masui et al, 1991) . The EGF receptor gene in these cells was not found to be rearranged or genetically altered, but the gene was found to be amplified in the range of 60-80 copies per cell, which is approximately twice the copy number Induction of apoptosis and activation of the caspase cascade by anti-EGF receptor monoclonal antibodies in DiFi human colon cancer cells do not involve the c-jun N-terminal kinase activity seen in A431 epidermoid carcinoma cells (Untawale et al, 1993) . DiFi cell cultures in log-phase growth secrete measurable amounts of TGF-α (347 pg per 10 6 cells per 24 h) into their culture medium and have approximately 4.8 × 10 6 receptors per cell (Gross et al, 1991; Untawale et al, 1993) . Although the apoptosis induced by the anti-EGF receptor mAb 225 is well documented, it is not known whether mAb 225 induces apoptosis by specifically blocking EGF receptor function or whether the apoptosis results from an incidental cross-reaction of mAb 225 with an unidentified cell surface protein, binding of which by mAb 225 can trigger an apoptotic pathway in DiFi cells. Additionally, the intracellular biochemical pathways by which mAb 225 induces apoptosis are still poorly understood.
Caspases are a family of cysteinyl aspartate-specific proteinases that mediate highly specific proteolytic cleavage events in dying cells. Although caspase-independent apoptosis may exist (Xiang et al, 1996; Susin et al, 1999) , several lines of evidence indicate that caspases are critical for apoptosis in most cases. Caspase activation correlates with the onset of apoptosis, and caspase inhibition attenuates apoptosis (Bump et al, 1995; Cohen, 1997; Tewari et al, 1995) . C. elegans mutants lacking the worm caspase CED-3 have a complete absence of developmental programmed cell death (Ellis and Horvitz, 1986) . Animals deficient in caspase-3, -8 or -9 die perinatally because of profound defects in developmental programmed cell death (Green, 1998) . Targeted deletion of caspase genes has shown a definitive role for caspase in apoptosis and inflammation (Green, 1998) . To understand the mechanism by which mAb 225 induces apoptosis, it is essential to explore whether and how the caspase cascade is involved in the antibodyinduced apoptosis.
In the current study, we examined a panel of four different mAbs (14E1, 108, 528 and 225) directed against individually distinct epitopes on the EGF receptors for their effects on inducing apoptosis. We found that each of the mAbs induced apoptosis in DiFi cells. We further demonstrated the involvement of caspases-3, -8 and -9 in mAb 225-induced apoptosis. Because mAb 225 binds to and blocks EGF receptor function and because activation of the c-jun N-terminal kinase-1 (JNK1) pathway with a concomitant repression of the MAP kinase cascade may result in apoptosis under certain circumstances, we therefore also investigated whether the JNK1 signaling pathway was involved in mAb 225-mediated activation of the caspase cascade and apoptosis in DiFi cells. We found that, while ultraviolet (UV) irradiation of DiFi cells strongly activated JNK1 and subsequently activated the caspase cascade and induced apoptosis, exposure of DiFi cells to mAb 225 did not activate JNK1.
MATERIALS AND METHODS

Materials
Anti-EGF receptor mAbs 225, 528, 108, and anti-HER2 mAb 4D5 (which we used as a control) were previously described (Fan et al, 1993c; Ye et al, 1999) . Anti-EGF receptor mAb 14E1 was kindly provided by the Ernst Schering Research Foundation (Berlin, Germany). Anti-poly (ADP-ribose) polymerase (PARP) mAb (clone C-2-10) was purchased from CHUL Research Center, Laval University (Quebec, Canada). Anti-caspase-3 mAb (clone 19) was obtained from Transduction Laboratories (Lexington, KY, USA). Anti-JNK1 mAb (clone G151-333) was purchased from PharMingen (San Diego, CA, USA). DEVD-CHO and z-VADfmk were obtained from CalBiochem Corp. (San Diego, CA, USA). Caspase-3 substrate Ac-DEVD-pNA, caspase-8 substrate Ac-IETD-pNA, and caspase-9 substrate Ac-LEHD-pNA were from Alexis Corp. (San Diego, CA, USA). Protein A-Sepharose beads used for immunoprecipitation were purchased from Repligen Corp. (Cambridge, MA, USA). All other reagents were purchased from Sigma Chemical (St. Louis, MO, USA) unless otherwise specified.
Cells and tissue culture
DiFi human colorectal adenocarcinoma cells were described previously (Wu et al, 1995; . The cells were maintained in a mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium (1:1, v/v) supplemented with 10% fetal bovine serum (FBS) in a 37°C humidified atmosphere containing 95% air and 5% CO 2 and were split twice a week.
Clonogenic assay
DiFi cells were seeded into 60 mm dishes at a density of 1000 cells per dish in 5 ml of medium containing 10% FBS and cultured for 15 days in a 37°C humidified atmosphere containing 95% air and 5% CO 2 . The cell clones were stained for 5 min with a solution containing 0.5% crystal violet and 25% methanol, followed by three rinses with tap water to remove excess dye.
Analysis of DNA fragmentation
Cells (approximately 1 × 10 6 ) were lysed with 200 µl of lysis buffer (50 mM Tris, pH 8.0, 10 mM EDTA, 0.5% N-lauroyl sarcosine, and 0.5 mg ml -1 proteinase K). The lysates were then incubated in a 50°C water bath for 1 h prior to the addition of heat-boiled RNase A to the final concentration of 0.5 mg ml -1 ; the lysates were then incubated for an additional hour in the 50°C water bath. After the digestion, the samples were diluted with an equal volume of TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA). DNA was extracted three times with phenol-chloroform-isoamyl alcohol (25:24:1, v/v/v) and precipitated with 0.2 × volume of 3 M ammonia acetate and 2 × volumes of ethyl alcohol. The DNA precipitates were dissolved in TE buffer, and 5 µg of DNA from each sample was analyzed by 1.5% agarose gel electrophoresis.
Quantification of apoptosis by ELISA
We used an apoptosis ELISA kit (Roche Diagnostics Corp., IN, USA) to quantitatively measure cytoplasmic histone-associated DNA fragments (mononucleosomes and oligonucleosomes) after induced cell death. This photomeric enzyme immunoassay was performed exactly according to the manufacturer's instructions.
Scanning and transmission electron microscopy
DiFi cells were rinsed in serum-free medium to remove unbound protein and were then treated with a fixative containing 3% glutaraldehyde and 2% paraformaldehyde in 0.1 M cacodylate buffer, pH 7.3 (Ted Pella, Inc., Redding, CA, USA) for 1 h at ambient temperature. After fixation, the cells were washed three times with 0.1 M Millipore-filtered cacodylate-buffered tannic acid, pH 7.3, and then post-fixed with 1% cacodylate-buffered osmium tetroxide (Electron Microscopy Sciences, Ft. Washington, PA, USA) for 1 h. The samples were prepared by standard procedures and examined in a Hitachi S-520 scanning electron microscope at an acceleration voltage of 5 kV and in a JEOL 1200-EX transmission electron microscope at an acceleration voltage of 80 kV.
Caspase enzymatic activity assay
Caspase enzymatic activities were measured by colourimetric assays with a kit purchased from Clontech Laboratories, Inc. (Palo Alto, CA, USA). The assay is based on spectrophotometric detection of the chromophore p-nitroanilide (pNA), which is cleaved from caspase-specific substrates by activated caspases (DEVDpNA by activated caspase-3, IETD-pNA by activated caspase-8, and LEHD-pNA by activated caspase-9). The assay was performed exactly according to the manufacturer's instructions.
Terminal deoxynucleotidyl transferase-mediated dUTP-X nick end labelling (TUNEL) assay
DiFi cells were harvested and fixed in 2% formaldehyde on ice for 15 min; the fixing solution was then removed and the cell pellets were washed once with PBS. Subsequently, the cells were postfixed in ice-cold 70% ethanol for 30 min, followed by washing the cells once with PBS and incubating the cells in 50 µl of terminal deoxynucleotidyl transferase (TdT) reaction solution containing 5 units of TdT, 0.5 nmol of biotin-dUTP, and 2.5 mM CoCl 2 in TdT buffer (purchased from Roche Diagnostics Corp.) at 37°C for 1 h. After the reaction, the cells were stained with a buffer containing 2.5 µg ml -1 FITC-avidin, 0.1% Triton X-100, 5% dried low-fat milk in 4 × SSC (0.6 M sodium chloride, 60 mM sodium citrate, pH 7) in the dark at room temperature for 1 h. Before flow cytometric analysis with a FACScan flow cytometer (Becton Dickinson, San Jose, CA, USA), the cells were counterstained with a solution containing 5 µg ml -1 propidium iodide and 10 µg ml -1 RNase A in PBS. The FITC signal was analysed with Epics Elite software (Coulter Corp., Miami, FL, USA).
Western blot analysis
Equal amounts of protein were used for western blot analysis with the indicated antibodies. Briefly, cells were lysed in a lysis buffer containing 50 mM Tris, pH 7.4, 50 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 25 µg ml -1 leupeptin, and 25 µg ml -1 aprotinin. The lysates were centrifuged at the full speed of a microcentrifuge for 15 min and the supernatants were collected for protein concentration determination, SDS-PAGE, and western blot analysis with specific antibodies as described in the figure legends.
Purification of GST-c-jun fusion protein
DH5α bacteria transformed with plasmid pGEX-c-jun (kindly provided by Dr B Su at The University of Texas MD Anderson Cancer Center, Houston, TX, USA) were grown in LB medium. After induction with 0.1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) for 2 h, the bacteria were harvested and resuspended in EBC lysis buffer (20 mM Tris, pH 7.4, 50 mM NaCl, 0.5% NP-40, 1% Triton X-100) containing 0.1 µg ml -1 leupeptin, 0.04 U ml -1 aprotinin, and 1 mM phenylmethylsulphonyl fluoride. The bacteria were sonicated three times at 4°C for 10 s each time and then centrifuged at the full speed of a microcentrifuge at 4°C for 5 min. The supernatants were transferred to a new tube with the addition of 100 µl of 50% glutathione sepharose 4B slurry (Pharmacia Biochech Inc., Piscataway, NJ, USA). The mixture was incubated on a rotator at 4°C for 2 h, and the Sepharose 4B beads were then collected by half-full speed microcentrifugation for 15-30 s and then washed with EBC lysis buffer three times. The GST-c-jun fusion protein was eluted by an elution buffer (10 mM glutathione, 50 mM Tris, pH 8.0) and stored at -80°C in aliquots.
JNK1 kinase assay
Cells were lysed with a buffer containing 50 mM Tris, pH 7.4, 50 mM NaCl, 0.5% NP-40, 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM phenylmethylsulfonyl fluoride, 25 µg ml -1 leupeptin, and 25 µg ml -1 aprotinin. JNK1 was immunoprecipitated from 50 µg of lysate with 1 µg of specific anti-JNK1 mAb (clone G151-333) at 4°C for 3 h and with a 20 µl bed volume of protein A-Sepharose for another 3 h. The immunoprecipitates were washed three times with the lysis buffer and twice with a kinase buffer (20 mM Tris, 7.5 mM MgCl 2 , 1 mM dithiothreitol). The kinase reaction was performed by incubating the immunoprecipitates with 40 µl of kinase buffer containing 2 µg of GST-c-jun, 25 µM lithium ATP, and 5 µCi of [γ-32 P]ATP (New England Nuclear, Boston, MA, USA) at 30°C for 30 min. The reaction was terminated by boiling the samples with 40 µl of 2 × SDS sample buffer. The products of the reaction were resolved using 10% SDS-PAGE and subjected to autoradiography.
RESULTS
Apoptosis induced by mAbs directed against the EGF receptors and its characteristics
In 1995, we first reported that exposure of DiFi cells to mAb 225 resulted in cell death through apoptosis (Wu et al, 1995) . To further explore the generality of the apoptosis induced by anti-EGF receptor antibodies, we examined the effects of a panel of four different anti-EGF receptor mAbs (14E1, 108, 528 and 225) on the induction of apoptosis in DiFi cells. These antibodies bind to individually distinct epitopes on the extracellular domain of the EGF receptor and block the binding of natural ligands to the receptor (Fan et al, 1993c; Schmidt et al, 1997) . As a control, we used the mAb 4D5 (Herceptin), which is directed against the extracellular domain of HER-2, a structurally similar receptor of the EGF receptor superfamily. Cell death was observed 24 h after the cells were exposed to these antibodies in medium containing 0.5% FBS. Treated and untreated cells were lysed, and chromosomal DNA was prepared for agarose gel electrophoresis analysis to demonstrate the characteristic DNA fragmentation (ladder) (Wu et al, 1995) . We found that exposure of the DiFi cells to any of the four anti-EGF receptor mAbs produced a characteristic DNA ladder, which was not observed in the untreated cells or in cells treated with the anti-HER-2 mAb 4D5 ( Figure 1A) .
We further characterized the mAb dose-and time-dependency of mAb 225-induced apoptosis. The mAb 225-induced apoptosis was concentration dependent ( Figure 1B) . The initial effective dose determined by DNA fragmentation electrophoresis analysis was greater than 5 nM of mAb 225. However, the dose required to induce apoptosis was lower (1-2 nM) with a more sensitive apoptosis ELISA analysis (data not shown). DNA fragmentation was first detectable approximately 12 h after continuous exposure of the cells to 20 nM mAb 225 ( Figure 1C ). However, a 1 h exposure of the cells to 20 nM mAb 225 was sufficient to induce apoptosis that was measured 24 h later ( Figure 1D ). The percentage of the cells that were apoptotic at 24 h after 1 h of incubation with mAb 225 was approximately 25-30% by Hoechst (#33258) dye staining. This result was similar to the percentage of the cells that were apoptotic after being continuously exposed to mAb 225 for 24 h (data not shown).
A caveat is that the dose-dependent induction of DNA fragmentation by mAb 225 in Figure 1B does not necessarily reflect a similar pattern of end-point of cell survival. The clonogenic survival shown in Figure 2 indicates that, in a 15-d culture period, there were no differences in clone survival of the cells exposed to the serial concentrations of mAb 225 that were used in Figure 1B .
The mAb 225-induced apoptosis in DiFi cells was characterized with typical morphological changes in the cell membrane, the nuclei, and the mitochondria. Scanning electron micrography shows that untreated DiFi cells displayed features typical of colon epithelial cells, i.e. an abundance of delicate microvilli that were orderly and closely packed on the cell surface, whereas mAb 225-treated cells exhibited volume shrinkage, distortion of cell surface microvilli, and the appearance of elongated membrane blebbings ( Figure 3A) . Transmission electron micrography showed that untreated cells contained intact nuclei and mitochondria filled with integral cristae whereas the antibody-treated cells developed fragmented nuclei, membrane-wrapped apoptotic bodies, and swollen mitochondria ( Figure 3B and 3C) . On the next day, the cells were exposed to the indicated concentrations of mAb 225 and cultured in a 37°C incubator with 95% air and 5% CO 2 for 15 days. The cell clones were stained with crystal violet blue.
Role of the execution caspase-3 in mAb 225-induced apoptosis
Caspase-3 is a major execution caspase required for the characteristic DNA fragmentation ( Figure 1 ) and morphological changes ( Figure 3 ) associated with apoptosis (Janicke et al, 1998a) . To demonstrate whether treatment of DiFi cells with mAb 225 triggers a cascade that results in activation of caspase-3, we measured the enzyme activity of caspase-3 following exposure of DiFi cells to mAb 225. We found a time-dependent activation of caspase-3, which was detectable between 8 h and 16 h after exposure of DiFi cells to mAb 225 ( Figure 4A ). This activation of caspase-3 coincided with cleavage of the 116-kDa PARP, one of welldocumented substrates for activated caspase-3 ( Figure 4B ). The appearance of a characteristic 85-kDa PARP fragment was observed temporally with activation of caspase-3, as shown by the reduced level of the 32-kDa proenzyme due to its cleavage by its upstream caspases. Our results suggest that the apoptosis induced by mAb 225 in DiFi cells involves the caspase-3 activity. We further explored whether there was a causal correlation of caspase-3 activation and mAb 225-induced PARP cleavage by selectively blocking caspase-3 activity with specific synthetic peptide inhibitors. When DiFi cells were exposed to the caspase-3 specific inhibitor DEVD-CHO, the caspase-3 activity was markedly inhibited 24 h after exposure of cells to mAb 225 ( Figure  4C ). Inhibition of caspase-3 with DEVD-CHO partially reduced the rate of PARP cleavage after mAb 225 treatment. Cleavage of PARP was detected as early as 8 h after treatment with mAb 225 alone ( Figure 4D, lanes 2 and 3) , but when the cells were pre-incubated with DEVD-CHO the cleavage was not detected until 24 h after treatment ( Figure 4D, lanes 4 and 5) . Pre-incubation of the cells with a pan-caspase inhibitor, z-VAD-fmk, more strongly prevented cleavage of PARP by mAb 225 than did DEVD-CHO ( Figure 4D , lanes 6 and 7). Compared with the results of mAb 225 treatment alone, the cells pre-incubated with DEVD-CHO or z-VAD-fmk retained relatively higher levels of the 116-kDa PARP at both the 8 h and 24 h time-points ( Figure 4D , lane 2 compared with lanes 4 and 6, and lane 3 compared with lanes 5 and 7, respectively), especially when the pan-caspase inhibitor z-VAD-fmk was used.
We accordingly evaluated the effects of these caspase inhibitors on mAb 225-induced apoptosis. TUNEL assay showed that, compared with results for mAb 225 treatment alone, the relative percentage of apoptotic cells (FITC-positive cells) was lower in the cells pre-treated with DEVD-CHO or z-VAD-fmk 12 h before the cells were exposed to mAb 225 ( Figure 5A ), and this result was also consistent with the PARP cleavage analysis indicating that z-VAD-fmk was a stronger inhibitor than DEVD-CHO in preventing mAb 225-induced PARP cleavage and apoptosis ( Figure 5B ). The FITC-positive rates varied from 10-30% of total cells in several repeated experiments in our study, depending upon the intensity of FITC that was conjugated to the avidin used in the TUNEL assay. However, in each experiment, the relative fold increase of the FITC-positive rate in mAb 225-treated cells over that in untreated cells was consistent ( Figure 5A ). Parallel experiments analysed by chromosomal DNA agarose gel electrophoresis had similar results ( Figure 5B ). In these experiments, the pan-caspase inhibitor z-VAD-fmk more strongly inhibited mAb 225-induced apoptosis than did DEVD-CHO. These results indicated that activation of caspase-3 is a major step in mAb 225-induced apoptosis but also that caspase-3 may not be the only caspase contributing to the apoptosis.
Activation of the initiation caspase-8 and caspase-9 in mAb 225-induced apoptosis
We measured the specific activities of the initiation caspases-8 and -9 following exposure of DiFi cells to mAb 225. We found a timedependent activation of caspase-8, which was detectable between 8 h and 16 h after exposure of the cells to mAb 225 ( Figure 6A ). There was also an activation of caspase-9, which lagged a few hours behind the activation of caspase-8. These results indicate that both the caspase-8-initiated and the caspase-9-initiated caspase cascades are activated in the apoptosis induced by mAb 225 in these cells. UV irradiation of DiFi cells for 40 s also activated the initiation caspases-8 and -9 ( Figure 6B ) and the execution caspase-3 (data not shown). However, compared with the kinetics of the caspase cascade activation by mAb 225, which showed relative delayed but steady increases in the caspase activities over 24 h, the activation of caspase-8 and caspase-9 by UV was detected 4 h shortly after the treatment and reached a plateau afterward.
Lack of involvement of the JNK signalling pathway in mAb 225-induced apoptosis
Recent study has suggested possible interactions, under certain circumstances, between the JNKs pathway and the caspase cascade during apoptosis (Lei et al, 1998; Muhlenbeck et al, 1998; Shiah et al, 1999) . JNKs participate in cellular responses to environmental stresses, apoptotic agents, and even some mitogenic stimuli (Chen et al, 1996) . To investigate possible involvement of the JNK signaling pathway in mAb 225-induced apoptosis and activation of the caspase cascade in DiFi cells, we examined the JNK1 kinase activity when DiFi cells were exposed to mAb 225. Exposure of DiFi cells to either mAb 225 or UV irradiation induced apoptosis ( Figure 7A and 7B). However, only the UV irradiation activated JNK1 kinase ( Figure 7C ). The levels of JNK1 protein remained unchanged during the exposure period to mAb 225 or UV irradiation. This result indicated that the JNK1 signaling pathway is competent in DiFi cells but that it is not involved in mAb 225-induced apoptosis in DiFi cells.
DISCUSSION
A human-mouse chimeric version of mAb 225 (C225) is currently being evaluated in clinical trials of its antitumour activity against human cancers of the pancreas, colon, and head and neck.
Ongoing studies are investigating a potential synergy between the anti-EGF receptor mAb 225-mediated disruption of EGF receptor function and conventional chemotherapy or radiation therapy (Baselga et al, 2000; Perez-Soler et al, 1998; Mendelsohn et al, 1999) . Because a direct and targeted approach to cancer therapy is preferable, demonstration of the mechanism by which mAb 225 induces apoptosis specifically in DiFi colorectal cancer cells may direct us to develop new therapeutic strategies that will maximize the antitumour activity of mAb 225 by inducing programmed cell death in a broad range of human cancers without requiring combination treatment with conventional chemotherapy or radiation therapy.
In the present study, we demonstrated that apoptosis was induced by several different mAbs that recognize individual distinct epitopes on the EGF receptors on DiFi cells. This result makes it unlikely that mAb 225 induces apoptosis by cross-reacting with an unidentified 'death' protein rather than the EGF receptor on DiFi cell surfaces. The commitment of DiFi cells to apoptosis shortly after 1 h of exposure to mAb 225 sharply contrasts with the antiproliferative activity of mAb 225 in many other cell lines, which normally requires over 24 h of continuous exposure of the cells to the antibody to arrest cell cycle progression, suggesting that the apoptotic activity of anti-EGF receptor mAb in DiFi cells may not be directly associated with the anti-proliferative effect of mAb 225 on many other cell lines. We also demonstrated that caspases-3, -8 and -9 are activated during mAb 225-induced apoptosis and the latter apoptosis differs from the apoptosis of DiFi cells induced by UV irradiation in that it does not involve JNK1 activity. In other studies, JNK1 activity was associated with activation of caspases by several anticancer drugs (Seimiya et al, 1997; Shiah et al, 1999) . In our study, the JNK1 activity was temporally associated with the activation of caspases-3, -8 and -9 during UV irradiationinduced apoptosis, suggesting a competent JNK signalling pathway in DiFi cells during the apoptosis. However, this was not the case in the activation of the caspase cascade during mAb 225-induced apoptosis in these cells. An understanding of caspase regulation is intimately linked to the ability of researchers to rationally manipulate apoptosis for therapeutic application to human cancer. Caspases are constitutively expressed as latent proenzymes in living cells. Two initiation pathways of caspase cascade during apoptosis have been described (Thornberry and Lazebnik, 1998; Ashkenazi and Dixit, 1998; Green and Reed, 1998; Sun et al, 1999) . The first pathway is the caspase-8 initiated apoptosis induced by death receptors, such as Fas or tumour necrosis factor (TNF) receptors (Boldin et al, 1996; Muzio et al, 1996; 1998; Yang et al, 1998) ; the second pathway involves the complex of cytochrome c, Apaf-1 and caspase-9 following stimulation of the cells with diverse proapoptotic signals that converge at the mitochondrial level and provoke the translocation of cytochrome c from the mitochondria to the cytoplasm (Kluck et al, 1997; Adachi et al, 1997; Kharbanda et al, 1997; Kim et al, 1997; Bossy-Wetzel et al, 1998) . The characteristic induction of apoptosis by anti-EGF receptor mAb is reminiscent of the apoptosis induced by anti-fas/CD95 mAb (Itoh et al, 1991) . We examined the possible involvement of the fas-mediated apoptotic pathway in mAb 225-induced apoptosis. Exposure of DiFi cells to an anti-fas mAb did not trigger apoptosis, suggesting that DiFi cells do not constitutively express functional fas (data not shown). The apoptosis induced by the anti-EGF receptor mAb has so far been observed only in DiFi colon cancer cells. In most tumour cell lines studied, blockade of the EGF receptor with mAb has resulted in cell cycle arrest rather than cell death. Two possible mechanisms by which anti-EGF receptor mAbs induce apoptosis are being considered. The first possibility is that the DiFi cells may be genetically defective in certain components that normally inhibit induction of apoptosis upon EGF receptor blockade. Alternatively, the EGF receptor in DiFi cells may link to molecule(s) that have apoptosis-triggering activity, and binding of the receptor by mAb may result in a release or activation of such molecule(s). Both caspase-8 and caspase-9 may initiate caspase cascade and thereby induce apoptosis, however, we speculate that the observed activation of caspase-9 in DiFi cells after mAb 225 treatment could be a consequence of mAb 225-induced activation of caspase-8 through a mechanism similar to fas-mediated activation of caspase-8 and caspase-9. Caspase-8 activated by fas pathway can cleave Bid (a BH3 domain-containing proapoptotic Bcl-2 family member), and the truncated Bid will then translocate to the mitochondria and induce the release of cytochrome c and subsequent activation of caspase-9 (Li et al, 1998) . Our data showing that the kinetics of caspase-9 activation lagged a few hours behind the activation of caspase-8 support this speculation (Figure 6 ).
Among the known execution caspases (caspase-3, -6 and -7, etc), caspase-3 is the major caspase. Induction of apoptosis in caspase-3-defective MCF-7 human breast cancer cells was accompanied by cleavage of PARP, Rb, and DNA-PK without concurrent appearance of the characteristic DNA internucleosomal degradation and the characteristic morphological changes associated with apoptosis; however, introduction of caspase-3 cDNA into the MCF-7 cells restored α-fodrin cleavage and membrane blebbing (Janicke et al, 1998a; 1998b) . The characteristic induction of DNA laddering and membrane blebbing in DiFi cells that we observed following treatment with mAb 225 (Figures 1 and 3 ) led us to examine the involvement of caspase-3 in mAb 225-induced apoptosis in DiFi cells. Our data indicate that caspase-3 is a major caspase contributing to apoptosis in DiFi cells. In addition, this pathway also involves activation of caspase-8 and caspase-9. Inhibition of caspase-3 and pan-caspase activities by specific inhibitors strongly reduced induction of the apoptosis with concomitant inhibition of PARP cleavage and DNA fragmentation.
Caspases contribute to apoptosis in a tissue-or cell type-specific or death signal-specific manner. Caspase-3-disrupted cells that were highly resistant to apoptosis induced by UV irradiation or osmotic shock were still sensitive to apoptosis induced by γ-irradiation or heat shocks (Woo et al, 1998) . The demonstration of the involvement of the caspase cascade (the initiation caspases-8 and -9 and the execution caspase-3) in mAb 225-induced apoptosis provides important insights for us to further pursue the mechanism.
In summary, we demonstrated that apoptosis could be induced in DiFi colon cancer cells by a variety of anti-EGF receptor mAbs that bind to different epitopes on the receptor. This apoptosis is characterized by classical DNA internucleosomal degradation and typical caspase-mediated morphological changes, and this apoptosis involves activation of caspase-8-and caspase-9-initiated caspase cascade. We are currently investigating the biochemical pathway(s) by which mAb 225 induces activation of the caspase cascade, thereby triggering apoptosis.
